Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
23. Oktober 2024 09:00 ET
|
Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Adial Pharmaceuticals Featured on CBS in San Francisco
28. Februar 2019 09:15 ET
|
Adial Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for...
Adial Pharmaceuticals Announces Closing of $9.2 Million Underwritten Public Offering and Exercise of Underwriters’ Over-Allotment Option
26. Februar 2019 08:00 ET
|
Adial Pharmaceuticals, Inc.
Proceeds from Offering Expected to Fully Fund Initial Phase 3 Trial of AD04 CHARLOTTESVILLE, Va., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage...
Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
21. Februar 2019 08:45 ET
|
Adial Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for...
Adial Pharmaceuticals Announces Partnership with Catalent to Package and Distribute Adial’s AD04 for its Phase 3 Trial
20. Februar 2019 09:00 ET
|
Adial Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of...
Adial Pharmaceuticals Submits Continuation Patent Application for Use of AD04 in Opioid Dependence and Abuse
15. Februar 2019 08:30 ET
|
Adial Pharmaceuticals, Inc.
Continuation patent would allow for broader protection beyond claims protected under current patents CHARLOTTESVILLE, Va., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc....
Adial Pharmaceuticals Appoints Leading Addiction Specialist to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder
12. Februar 2019 09:33 ET
|
Adial Pharmaceuticals, Inc.
Distinguished Professor Markus Heilig joins an accomplished assemblage of addiction specialists including Dr. Giovanni Addolorato and Professors Hannu Alho, Tomas Zima and Sebastian Mueller ...
Dr. Bankole A. Johnson, Chairman of Adial Pharmaceuticals, Receives Prestigious American Society of Addiction Medicine Award
07. Februar 2019 09:15 ET
|
Adial Pharmaceuticals, Inc.
Dr. Johnson Recognized for Advancing Scientific Understanding of Alcoholism and its Prevention CHARLOTTESVILLE, Va., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;...
Adial Pharmaceuticals CEO to Appear on CBS and Fox Affiliates to Discuss AD04 as a Potential Treatment for Alcohol and Opioid Use Disorder
01. Februar 2019 09:20 ET
|
Adial Pharmaceuticals, Inc.
Scheduled to appear today on KSWB-TV FOX 5 Morning News in San Diego at 10:40 AM ET/7:40 AM PT Additional appearance scheduled on KPIX-TV (CBS-CW) “Bay Area Focus” morning show February 3rd during...
Adial Pharmaceuticals Receives $1.2 Million in Proceeds Through the Exercise of Warrants
24. Januar 2019 08:30 ET
|
Adial Pharmaceuticals, Inc.
Enhances Balance Sheet; Funds to be Utilized for Phase 3 Clinical Trial of AD04 CHARLOTTESVILLE, Va., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW)...